Mount Sinai Researchers Move Closer t... - Lung Conditions C...

Lung Conditions Community Forum

56,014 members66,643 posts

Mount Sinai Researchers Move Closer to a Universal Influenza Vaccine.

2greys profile image
1 Reply

Researchers at Mount Sinai School of Medicine have developed a new influenza vaccine that brings science one step closer to a universal influenza vaccine that would eliminate the need for seasonal flu shots. The new findings can be found in the inaugural issue of mBio®, the first online, open-access journal published by the American Society for Microbiology.

"Current influenza vaccines are effective against only a narrow range of influenza virus strains," said Peter Palese, Ph.D., Professor and Chair of the Department of Microbiology at Mount Sinai School of Medicine. "This new vaccine brings us closer to our ultimate goal of a vaccine that protects against multiple strains.”

mountsinai.org/about/newsro...

Written by
2greys profile image
2greys
To view profiles and participate in discussions please or .
Read more about...
1 Reply
RoadRunner44 profile image
RoadRunner44

Thanks for keeping us informed 2greys. Useful in formation as usual from you.

Not what you're looking for?

You may also like...

Mount Sinai Researchers Develop Novel Method to Identify Patterns Among Patients With Multiple Chronic Conditions.

A study published this month in BMJ Open by researchers at Icahn School of Medicine at Mount Sinai...

A step toward a universal flu vaccine.

Each year, the flu vaccine has to be redesigned to account for mutations that the virus...

Most People Mount a Strong Antibody Response to SARS-CoV-2 That Does Not Decline Rapidly.

The vast majority of individuals infected with mild-to-moderate COVID 19 mount a robust antibody...

New Landmark Study at UM School of Medicine Finds Aspirin Use Reduces Risk of Death in Hospitalized COVID-19 Patients.

Hospitalized COVID-19 patients who were taking a daily low-dose aspirin to protect against...

‘Universal Covid vaccine’ could be developed within a year, Second-generation jab may work against all variants of coronavirus.

Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies is pleased to announce...